DK0736039T3 - Forbindelser med væksthormon-frigivende egenskaber - Google Patents

Forbindelser med væksthormon-frigivende egenskaber

Info

Publication number
DK0736039T3
DK0736039T3 DK95903774T DK95903774T DK0736039T3 DK 0736039 T3 DK0736039 T3 DK 0736039T3 DK 95903774 T DK95903774 T DK 95903774T DK 95903774 T DK95903774 T DK 95903774T DK 0736039 T3 DK0736039 T3 DK 0736039T3
Authority
DK
Denmark
Prior art keywords
growth hormone
compounds
pct
releasing properties
date jun
Prior art date
Application number
DK95903774T
Other languages
Danish (da)
English (en)
Inventor
Nils Langeland Johansen
Behrend Friedrich Lundt
Jesper Lau
Kjeld Madsen
Gersen Henning Th
Birgit Sehested Hansen
Bernd Peschke
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK143993A external-priority patent/DK143993D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of DK0736039T3 publication Critical patent/DK0736039T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/60Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK95903774T 1993-12-23 1994-12-22 Forbindelser med væksthormon-frigivende egenskaber DK0736039T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK143993A DK143993D0 (ru) 1993-12-23 1993-12-23
DK12194 1994-01-28
DK119194 1994-10-14
PCT/DK1994/000485 WO1995017423A1 (en) 1993-12-23 1994-12-22 Compounds with growth hormone releasing properties

Publications (1)

Publication Number Publication Date
DK0736039T3 true DK0736039T3 (da) 2001-02-12

Family

ID=27220421

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95903774T DK0736039T3 (da) 1993-12-23 1994-12-22 Forbindelser med væksthormon-frigivende egenskaber

Country Status (27)

Country Link
US (1) US5767085A (ru)
EP (1) EP0736039B1 (ru)
JP (1) JP3181918B2 (ru)
KR (1) KR100354897B1 (ru)
CN (1) CN1052731C (ru)
AT (1) ATE197158T1 (ru)
AU (1) AU689181B2 (ru)
BR (1) BR9408377A (ru)
CA (1) CA2179597A1 (ru)
CZ (1) CZ293113B6 (ru)
DE (1) DE69426206T2 (ru)
DK (1) DK0736039T3 (ru)
ES (1) ES2153469T3 (ru)
FI (1) FI962584A0 (ru)
GR (1) GR3035150T3 (ru)
HU (1) HU224345B1 (ru)
IL (1) IL112112A (ru)
MX (1) MX9500072A (ru)
NO (1) NO315561B1 (ru)
NZ (1) NZ277486A (ru)
PL (1) PL181280B1 (ru)
PT (1) PT736039E (ru)
RO (1) RO115635B1 (ru)
SG (1) SG55069A1 (ru)
SK (1) SK281963B6 (ru)
UA (1) UA42747C2 (ru)
WO (1) WO1995017423A1 (ru)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09505601A (ja) * 1993-11-24 1997-06-03 メルク エンド カンパニー インコーポレーテッド インドリル基含有化合物類および成長ホルモン放出を促進するためのそれらの使用
ATE202785T1 (de) * 1993-12-23 2001-07-15 Novo Nordisk As Verbindungen mit wachstumshormon-freisetzenden eigenschaften
US20020111461A1 (en) * 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
PL186511B1 (pl) 1995-01-27 2004-01-30 Novo Nordisk As Nowe związki peptydowe, kompozycje farmaceutycznedo pobudzania uwalniania hormonu wzrostu i zastosowanie tych związków do wytwarzania leku do pobudzania uwalniania hormonu wzrostu
BR9608909A (pt) * 1995-06-22 1999-03-02 Novo Nordisk As Composto composição farmacêutica processos para estimular a liberação do hormônio do crescimento da patuitária e aumentar a velocidade e extensão do crescimento dos animais para aumentar a produção de leite ou lã de animais ou para para doenças e uso do composto
CA2240186A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
CZ195098A3 (cs) * 1995-12-22 1998-10-14 Novo Nordisk A/S Sloučeniny uvolňující růstový hormon
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5919777A (en) * 1996-04-24 1999-07-06 Novo Nordisk A/S Compounds with growth hormone releasing properties
PL329413A1 (en) * 1996-04-24 1999-03-29 Novo Nordisk As Chemical compounds exhibiting properties capable to cause growth hormone release
US5922770A (en) 1996-07-22 1999-07-13 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1998008492A1 (en) * 1996-08-29 1998-03-05 Novo Nordisk A/S Transdermal delivery of peptides
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1998058950A1 (en) 1997-06-20 1998-12-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU766305B2 (en) 1998-01-16 2003-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
JP2002520011A (ja) 1998-07-13 2002-07-09 メルク・アンド・カンパニー・インコーポレーテッド 成長ホルモン分泌促進物質関連受容体および核酸
WO2000009538A2 (en) 1998-08-10 2000-02-24 Merck & Co., Inc. Canine growth hormone secretagogue receptor
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
KR100699404B1 (ko) * 1999-02-18 2007-03-23 가켄 세야쿠 가부시키가이샤 성장 호르몬 분비촉진제로서의 신규 아미드 유도체
AU4911500A (en) * 1999-06-04 2000-12-28 Novo Nordisk A/S Compositions for the treatment of the catabolic state of prolonged critical illness
EP1282437B1 (en) 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
KR20060012008A (ko) * 2003-05-19 2006-02-06 워너-램버트 캄파니 엘엘씨 제어된 입자 크기를 갖는 산화 티타늄을 함유하는 경질젤라틴 캡슐 및 그의 제조방법
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CA2538342C (en) 2003-09-12 2013-01-08 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
JP2007531769A (ja) * 2004-03-30 2007-11-08 サファイア セラピューティクス インコーポレイテッド 成長ホルモン分泌促進薬を使用したc−反応性蛋白質の低減方法
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2005272598B2 (en) * 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2021015A2 (en) * 2006-04-28 2009-02-11 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
WO2008100448A2 (en) * 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
WO2008134828A2 (en) 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
UA105657C2 (ru) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Улучшенные способы лечения мигрени на основе анаморелина
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
BRPI1012931A2 (pt) * 2009-06-12 2018-01-30 Helsinn Therapeutics Us Inc soluções para infusão e injeção de diacetato de ipamorelina
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
EP3601245A1 (en) 2017-03-28 2020-02-05 The Regents of The University of Michigan Small molecule dcn1 inhibitors and therapeutic methods using the same
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223019A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
BR8208035A (pt) * 1981-12-28 1983-11-22 Beckman Instruments Inc Peptideos sinteticos tendo atividade liberadora de hormonio do crescimento da pituitaria
US4803261A (en) * 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
WO1994007519A1 (en) * 1992-09-25 1994-04-14 Smithkline Beecham Corporation Growth hormone releasing peptides
JPH09505601A (ja) * 1993-11-24 1997-06-03 メルク エンド カンパニー インコーポレーテッド インドリル基含有化合物類および成長ホルモン放出を促進するためのそれらの使用

Also Published As

Publication number Publication date
PL315113A1 (en) 1996-10-14
NO962665L (no) 1996-08-23
BR9408377A (pt) 1997-08-19
FI962584A (fi) 1996-06-20
DE69426206D1 (de) 2000-11-30
HU224345B1 (hu) 2005-08-29
PT736039E (pt) 2001-04-30
ATE197158T1 (de) 2000-11-15
CZ293113B6 (cs) 2004-02-18
SG55069A1 (en) 1998-12-21
CN1052731C (zh) 2000-05-24
CZ183496A3 (en) 1997-02-12
SK82096A3 (en) 1997-01-08
SK281963B6 (sk) 2001-09-11
AU1272495A (en) 1995-07-10
JPH09507217A (ja) 1997-07-22
KR100354897B1 (ko) 2003-01-06
GR3035150T3 (en) 2001-04-30
DE69426206T2 (de) 2001-05-17
PL181280B1 (pl) 2001-07-31
ES2153469T3 (es) 2001-03-01
CA2179597A1 (en) 1995-06-29
CN1138335A (zh) 1996-12-18
AU689181B2 (en) 1998-03-26
IL112112A (en) 2000-06-29
HU9501947D0 (en) 1995-11-28
RO115635B1 (ro) 2000-04-28
NO962665D0 (no) 1996-06-21
NO315561B1 (no) 2003-09-22
FI962584A0 (fi) 1996-06-20
NZ277486A (en) 1997-03-24
MX9500072A (es) 1997-05-31
WO1995017423A1 (en) 1995-06-29
JP3181918B2 (ja) 2001-07-03
UA42747C2 (ru) 2001-11-15
US5767085A (en) 1998-06-16
IL112112A0 (en) 1995-03-15
HUT73497A (en) 1996-08-28
EP0736039A1 (en) 1996-10-09
EP0736039B1 (en) 2000-10-25

Similar Documents

Publication Publication Date Title
DK0736039T3 (da) Forbindelser med væksthormon-frigivende egenskaber
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
DK0804223T3 (da) Farmaceutiske præparater indeholdende hGH
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
DE69307895D1 (de) Therapeutische verwendung von phosphoryl-l-serin-n-acyl-sphingosin
BR9906975A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
AU6722498A (en) Disubstituted biphenyloxazolines
GB9015774D0 (en) Novel treatment
MX9710377A (es) Compuestos con propiedades de liberacion de la hormona de crecimiento.
NO960048D0 (no) Difluorstaton-analoger
CZ145095A3 (en) Novel triazoloquinazolines, process of their preparation and use
NO950114L (no) Amylin-antagonister og agonister
MY106292A (en) (alpha)-adrenergic receptor antagonists.
JO1711B1 (en) Therapeutic agents